Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00662571 · ClinicalTrials.gov registry record

Acamprosate: Genes Associated With Response

A clinical trial of Alcoholism, sponsored by Mayo Clinic.

Completed
Registry status
485
Enrollment target
1
Study location

NCT00662571 is a study of Alcoholism that has completed, run by Mayo Clinic. The registered enrollment target is 485 participants, above the 368-participant average among 65 other Alcoholism trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00662571, a study of Alcoholism, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
485 participants
Enrollment target
1
Study location

Study Summary

In 2004, acamprosate was approved in the U.S. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. Having the ability to identify treatment responsive individuals would have a major impact on the use of acamprosate.

Conditions Studied

Interventions

  • DRUG acamprosate

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 485 participants
Start Date 2008-05
Est. Completion 2013-02

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT00662571

The ClinicalTrials.gov registry entry for NCT00662571 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 368-participant average among 65 other Alcoholism trials with a reported enrollment target (32% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 1 intervention - of which acamprosate is the first listed.

NCT00662571 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00662571 about?

NCT00662571 is a clinical study titled "Acamprosate: Genes Associated With Response". In 2004, acamprosate was approved in the U.S. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. Having the abi...

What is the current status of trial NCT00662571?

This trial is currently completed. The enrollment target is 485 participants. The study started on 2008-05. Estimated completion is 2013-02.

What conditions does trial NCT00662571 study?

This clinical trial studies the following conditions: Alcoholism.

What interventions are being tested in trial NCT00662571?

The interventions under investigation include: acamprosate (DRUG).

Who is sponsoring clinical trial NCT00662571?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00662571 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.